Comparison of methods to monitor dogs with hypercortisolism treated with trilostane

J Vet Intern Med. 2021 Nov;35(6):2616-2627. doi: 10.1111/jvim.16269. Epub 2021 Oct 21.

Abstract

Background: The use of adrenocorticotropic hormone stimulation test as method to monitor efficacy of trilostane treatment of hypercortisolism (HC) in dogs has been questioned.

Objectives: To evaluate and compare 12 methods with which to monitor efficacy of trilostane treatment in dogs with HC.

Animals: Forty-five client-owned dogs with HC treated with trilostane q12h.

Methods: Prospective cross-sectional observational study. The dogs were categorized as well-controlled, undercontrolled, and unwell through a clinical score obtained from an owner questionnaire. The ability to correctly identify trilostane-treatment control of dogs with HC with the following variables was evaluated: before trilostane serum cortisol (prepill), before-ACTH serum cortisol, post-ACTH serum cortisol, plasma endogenous ACTH concentrations, prepill/eACTH ratio, serum haptoglobin (Hp) concentration, serum alanine aminotransferase (ALT), gamma-glutamyl transferase (γGT) and alkaline phosphatase activity, urine specific gravity, and urinary cortisol : creatinine ratio.

Results: Ninety-four re-evaluations of 44 dogs were included; 5 re-evaluations of 5 unwell dogs were excluded. Haptoglobin was significantly associated with the clinical score (P < .001) and in the receiver operating characteristic analysis, Hp cutoff of 151 mg/dL correctly identified 90.0% of well-controlled dogs (specificity) and 65.6% of undercontrolled dogs (sensitivity). Alanine aminotransferase (P = .01) and γGT (P = .009) were significantly higher in undercontrolled dogs. Cutoff of ALT and γGT greater than or equal to 86 U/L and 5.8 U/L, respectively, were significantly associated with poor control of HC by trilostane.

Conclusions and clinical importance: Of all the 12 variables, Hp, and to a lesser degree ALT and γGT, could be considered additional tools to the clinical picture to identify well-controlled and undercontrolled trilostane-treated dogs.

Keywords: Cushing; dog; monitoring; treatment.

Publication types

  • Observational Study, Veterinary

MeSH terms

  • Adrenocortical Hyperfunction* / drug therapy
  • Adrenocortical Hyperfunction* / veterinary
  • Animals
  • Cross-Sectional Studies
  • Cushing Syndrome* / veterinary
  • Dihydrotestosterone / analogs & derivatives
  • Dihydrotestosterone / therapeutic use
  • Dog Diseases* / drug therapy
  • Dogs
  • Enzyme Inhibitors
  • Hydrocortisone
  • Prospective Studies

Substances

  • Enzyme Inhibitors
  • Dihydrotestosterone
  • trilostane
  • Hydrocortisone

Grants and funding